

Value Architects Innovation SCORE Portfolio Trust (SERIES 2)

A 2 YEAR UNIT INVESTMENT TRUST

Investment Objective

The Trust seeks to provide investors with the possibility of above-average total return (a total return that exceeds that of the S&P 500 Index over the life of the Trust). The Portfolio Consultant sought to select securities whose historical, fundamental profitability metrics have generally been superior to industry peers or that possess significant amounts of intangible assets in the form of intellectual property. There is no guarantee that the investment objective of the Trust will be achieved.

Strategy of Portfolio Selection

The Trust seeks to achieve its objective through investment in the publicly traded common stock of companies. The portfolio was selected by Value Architects Asset Management LLC (the "Portfolio Consultant"). The Portfolio Consultant sought to select stocks of companies involved in aspects of health care, industrials and information technology. As used herein, the term "Securities" means the shares of common stocks of companies initially deposited in the Trust and contracts and funds for the purchase of such securities, and any additional securities acquired and held by the Trust pursuant to the provisions of the Trust Agreement.

Description of Portfolio

The portfolio of the Trust contains 36 issues of equity securities of domestic and foreign companies. 100% of the issues are represented by the Sponsor's contracts to purchase. Based upon the principal business of each issuer and current market values, the following sectors are represented by the common stocks of the companies in the portfolio: health care, 46.03%; industrials, 8.56%; and information technology, 45.41%.

INCEPTION DATE:	March 12, 2013
TERMINATION DATE:	March 12, 2015
INITIAL OFFER PRICE:	\$10.00
MINIMUM INVESTMENT:	100 units (May vary by selling firm.)
NUMBER OF ISSUES:	36
DISTRIBUTIONS: ¹	Monthly (if any)
ESTIMATED NET ANNUAL FIRST YEAR DISTRIBUTION PER UNIT: ²	\$0.1822
CUSIP (CASH):	83174R 106
CUSIP (REINVESTMENT):	83174R 114
FEE-BASED CUSIP (CASH):	83174R 122
FEE-BASED CUSIP (REINVESTMENT):	83174R 130
TICKER:	SMVIBX

Sales Charges³ (based on a \$10 public offering price):

STANDARD ACCOUNTS

Transactional Sales Charges:	Initial	1.00%
	Deferred	2.45%
Creation & Development Fee: ⁴		0.50%
Maximum Sales Charge:		3.95%

The deferred sales charge is a charge of \$0.245 per unit and will be deducted in three monthly installments commencing on July 20, 2013. Investors will not be assessed the initial and deferred sales charge for eligible fee-based accounts and must purchase units in a Fee CUSIP. Please see the prospectus for sales charge details.

FEE/WRAP ACCOUNTS

Creation & Development Fee: ⁴	0.50%
Maximum Sales Charge:	0.50%

¹Distributions, if any, will be made commencing on April 25, 2013. The estimated net annual distribution is expected to decline over time because a portion of the securities included in the portfolio will be sold to pay for organization costs, creation and development fee and deferred sales charge. Distributions will fluctuate as a result of Unitholder redemptions in addition to securities being sold within the portfolio. Distributions are also subject to the ability of issuers to make dividend payments in the future.

²Estimated Net Annual First Year Distribution per Unit is computed by dividing the estimated annual income of the underlying securities less the expense per unit by the number of units outstanding. The estimated net annual distributions for subsequent years are expected to be less than estimated distributions for the first year because a portion of the securities included in the Trust portfolio will be sold during the first year to pay for organization costs, the creation and development fee and the deferred sales charge. The actual net annual distributions will vary with changes in the Trust's fees and expenses and income of the underlying securities.

³Percentages are based on a \$10.00 per unit offering price. For unit prices other than \$10.00, percentages of initial sales charge, creation and development fee, and deferred sales charges will vary. Early redemption will still cause payment of the deferred sales charge. The table above shows the initial offering period sales charges only.

⁴The creation and development fee is a charge of \$.050 per unit collected at the end of the initial offering period. If the price you pay exceeds \$10 per unit, the creation and development fee will be less than 0.50%; if the price you pay is less than \$10 per unit, the creation and development fee will exceed 0.50%.

CONTINUED ON BACK.

Investors should consider the Trust's investment objective, risks, charges and expenses carefully before investing. The prospectus contains this and other information relevant to an investment in the Trust. Please advise your clients to read the prospectus carefully before they invest. If a prospectus did not accompany this literature, please contact SmartTrust at (888) 505-2872 to obtain a free prospectus.

HENNION & WALSH is a member of FINRA/SIPC.

2001 Route 46, Waterview Plaza, Parsippany, NJ 07054 **(888) 505-2872** www.smarttrustuit.com

NOT FDIC INSURED • NOT BANK GUARANTEED • MAY LOSE VALUE

Volume Discounts

PURCHASE AMOUNT ¹	SALES CHARGE
Less than \$100,000	3.95%
\$100,000 but less than \$250,000	3.45%
\$250,000 but less than \$500,000	3.20%
\$500,000 but less than \$750,000	2.95%
\$750,000 or greater	2.45%

¹The volume discount is also applied on a unit basis utilizing a breakpoint equivalent in the above table of one unit per \$10. Please see the Trust prospectus for full details. These discounts are only offered during the initial offering period.

Portfolio Holdings as of March 12, 2013

EQUITY SECURITIES — 100.00%

Health Care — 46.03%

AZN	AstraZeneca plc
BDX	Becton, Dickinson and Co.
CBM	Cambrex Corporation
CBPO	China Biologic Products Inc.
CBST	Cubist Pharmaceuticals Inc.
EBS	Emergent Biosolutions Inc.
GSK	GlaxoSmithKline plc
JAZZ	Jazz Pharmaceuticals plc
NVS	Novartis AG
PDLI	PDL BioPharma Inc.
POZN	POZEN Inc.
QSII	Quality Systems, Inc.
QCOR	Questcor Pharmaceuticals Inc.
SCLN	SciClone Pharmaceuticals, Inc.
TEVA	Teva Pharmaceutical Industries Ltd
UTHR	United Therapeutics Corporation
VAR	Varian Medical Systems, Inc.

Industrials — 8.56%

ACTG	Acacia Research Corporation
EXPX LN	Experian plc
NJ	Nidec Corporation

Information Technology — 45.41%

ACN	Accenture Plc
AAPL	Apple Inc.
AMAT	Applied Materials, Inc.
AVGO	Avago Technologies Ltd
BMC	BMC Software, Inc.
CA	CA, Inc.
CRUS	Cirrus Logic, Inc.
CSCO	Cisco Systems, Inc.
DLB	Dolby Laboratories, Inc.
INTC	Intel Corporation
KLIC	Kulicke and Soffa Industries Inc.
MSFT	Microsoft Corporation
NTES	NetEase, Inc
OTEX	Open Text Corporation
QLGC	QLogic Corporation
SIMO	Silicon Motion Technology Corp.

Risk Considerations

Unitholders can lose money by investing in this Trust. The value of the Units and the Securities included in the portfolio can each decline in value. An investment in Units of the Trust should be made with an understanding of the following risks:

- Since the portfolio of the Trust is unmanaged, in general, the Sponsor can only sell Securities under certain extraordinary circumstances, at the Trust's termination or in order to meet redemptions. As a result, the price at which each Security is sold may not be the highest price it attained during the life of the Trust.
- Price fluctuations of particular Securities will change the portfolio's composition throughout the life of the Trust. When cash or a letter of credit is deposited with instructions to purchase Securities in order to create additional Units, an increase in the price of a particular Security between the time of deposit and the time that Securities are purchased will cause the Units to be comprised of less of that Security and more of the remaining Securities. In addition, brokerage fees incurred in purchasing the Securities will be an expense of the Trust and such fees will dilute the existing Unitholders' interests.
- The risk that the financial condition of the issuers of the common stocks in the Trust may become impaired or that the general condition of the stock market may worsen (both of which may contribute directly to a decrease in the value of the Securities and thus in the value of the Units).
- The Trust is considered to be concentrated in securities issued by companies in the health care and information technology sectors. Negative developments in these sectors will affect the value of your investment more than would be the case in a more diversified investment.
- Securities of foreign companies held by the Trust present risks beyond those of U.S. issuers. These risks may include market and political factors related to the company's foreign market, international trade conditions, less regulation, smaller or less liquid markets, increased volatility, differing accounting practices and changes in the value of foreign currencies.
- The Trust may invest in companies with smaller market capitalizations, which may have less liquid stock and more volatile prices than larger capitalized companies. Such companies also tend to have unproven track records and, to a certain extent, are more likely to perform less well or fail than companies with larger market capitalizations.
- There is no assurance that any dividends will be declared or paid in the future on the Securities.
- The sponsor may offer successive Trusts with similar portfolios thereby allowing the investor to pursue the same strategy over a number of years. Investors should consider their ability to pursue investing in successive Trusts, if available. There may be tax consequences associated with investing in the Trust and rolling over an investment from one Trust to the next.

Portfolio Allocation as of March 12, 2013

